Clene Inc. Reports Continued Financial Losses in Q3 2025

Tip Ranks
2025.11.14 04:45
portai
I'm PortAI, I can summarize articles.

Clene Inc., a clinical-stage pharmaceutical company, reported a net loss of $8.8 million in Q3 2025, up from $8.0 million the previous year. Revenue was minimal at $15,000, and cash reserves fell to $7.9 million. The company faces a stockholders' deficit of $12.4 million and challenges in securing additional financing. Management is implementing cost-saving measures and exploring funding options, but the company's future remains uncertain.

Clene Inc ( (CLNN) ) has released its Q3 earnings. Here is a breakdown of the information Clene Inc presented to its investors.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Clene Inc. is a clinical-stage pharmaceutical company focused on developing nanotechnology therapeutics for neurological disorders, including ALS, MS, and Parkinson’s disease. In its latest earnings report, Clene Inc. revealed a continued struggle with financial losses, reporting a net loss of $8.8 million for the third quarter of 2025, compared to a $8.0 million loss in the same period last year. The company’s revenue remained minimal, with only $15,000 generated in the quarter, highlighting its ongoing reliance on external funding to support its operations. Clene’s financial position showed a decrease in cash and cash equivalents to $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. The company also reported a significant stockholders’ deficit, which increased to $12.4 million by the end of the third quarter. Looking ahead, Clene Inc. faces substantial challenges in securing additional financing to continue its operations and advance its drug development programs. The management has implemented cost-saving measures and is exploring various funding options, but the company’s future remains uncertain as it seeks to overcome its financial hurdles.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.